Clinical trial generates promising results for obinutuzumab in patients with lupus nephritis

In a post hoc analysis of the Phase II NOBILITY trial, researchers found that treatment with obinutuzumab—an antibody that targets a protein expressed on certain immune cells—was superior to placebo for preserving kidney function and preventing flares in patients with lupus nephritis, a kidney condition associated with the autoimmune disease lupus.